|MDACC Study No:||2013-0569 (clinicaltrials.gov NCT No: NCT01881789)|
|Title:||Phase Ib/2, Multicenter, Open-Label Study of Oprozomib and Dexamethasone in Combination With Lenalidomide or Oral Cyclophosphamide in Patients with Newly Diagnosed Multiple Myeloma|
|Principal Investigator:||Jatin J. Shah|
|Treatment Agent:||Cyclophosphamide; Dexamethasone; Lenalidomide; oprozomib|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of oprozomib that can be given in combination with lenalidomide (Revlimid) and
dexamethasone or cyclophosphamide and dexamethasone to patients with MM. The
safety of oprozomib will also be studied.